179 related articles for article (PubMed ID: 34744753)
1. Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant
Srivastava S; Gumbo T; Thomas T
Front Pharmacol; 2021; 12():776969. PubMed ID: 34744753
[No Abstract] [Full Text] [Related]
2. Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against
Srivastava S; Thomas T; Howe D; Malinga L; Raj P; Alffenaar JW; Gumbo T
Front Pharmacol; 2021; 12():677005. PubMed ID: 34163361
[No Abstract] [Full Text] [Related]
3. Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant
Singh S; Gumbo T; Boorgula GD; Thomas TA; Philley JV; Srivastava S
Antimicrob Agents Chemother; 2024 Feb; 68(2):e0108023. PubMed ID: 38131673
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children.
Srivastava S; van Zyl J; Cirrincione K; Martin K; Thomas T; Deshpande D; Alffenaar JW; Seddon JA; Gumbo T
Pediatr Infect Dis J; 2020 Dec; 39(12):1092-1100. PubMed ID: 32773662
[TBL] [Abstract][Full Text] [Related]
5. Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.
Deshpande D; Srivastava S; Bendet P; Martin KR; Cirrincione KN; Lee PS; Pasipanodya JG; Dheda K; Gumbo T
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180526
[TBL] [Abstract][Full Text] [Related]
6. Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Srivastava S; Bendet P; Koeuth T; Bhavnani SM; Ambrose PG; Smythe W; McIlleron H; Thwaites G; Gumusboga M; Van Deun A; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S274-S283. PubMed ID: 30496459
[TBL] [Abstract][Full Text] [Related]
7. d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.
Deshpande D; Alffenaar JC; Köser CU; Dheda K; Chapagain ML; Simbar N; Schön T; Sturkenboom MGG; McIlleron H; Lee PS; Koeuth T; Mpagama SG; Banu S; Foongladda S; Ogarkov O; Pholwat S; Houpt ER; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S308-S316. PubMed ID: 30496460
[TBL] [Abstract][Full Text] [Related]
8. Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model.
Srivastava S; Chapagain M; van Zyl J; Deshpande D; Gumbo T
J Glob Antimicrob Resist; 2021 Mar; 24():403-410. PubMed ID: 33508482
[TBL] [Abstract][Full Text] [Related]
9. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
[TBL] [Abstract][Full Text] [Related]
10. Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.
van Rijn SP; Srivastava S; Wessels MA; van Soolingen D; Alffenaar JC; Gumbo T
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696238
[TBL] [Abstract][Full Text] [Related]
11. Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.
Mallikaarjun S; Chapagain ML; Sasaki T; Hariguchi N; Deshpande D; Srivastava S; Berg A; Hirota K; Inoue Y; Matsumoto M; Hafkin J; Geiter L; Wang X; Gumbo T; Liu Y
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33106263
[TBL] [Abstract][Full Text] [Related]
12. Once-a-week tigecycline for the treatment of drug-resistant TB.
Deshpande D; Magombedze G; Srivastava S; Bendet P; Lee PS; Cirrincione KN; Martin KR; Dheda K; Gumbo T
J Antimicrob Chemother; 2019 Jun; 74(6):1607-1617. PubMed ID: 30820554
[TBL] [Abstract][Full Text] [Related]
13. Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating
Srivastava S; Cirrincione KN; Deshpande D; Gumbo T
Front Pharmacol; 2020; 11():616294. PubMed ID: 33542690
[No Abstract] [Full Text] [Related]
14. Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration.
Gumbo T; Sherman CM; Deshpande D; Alffenaar JW; Srivastava S
Int J Infect Dis; 2021 Mar; 104():680-684. PubMed ID: 33556616
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
[TBL] [Abstract][Full Text] [Related]
16. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
[TBL] [Abstract][Full Text] [Related]
17. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.
Srivastava S; Modongo C; Siyambalapitiyage Dona CW; Pasipanodya JG; Deshpande D; Gumbo T
Antimicrob Agents Chemother; 2016 Oct; 60(10):5922-7. PubMed ID: 27458215
[TBL] [Abstract][Full Text] [Related]
18. Ertapenem's therapeutic potential for Mycobacterium avium lung disease in the hollow fiber model.
Deshpande D; Srivastava S; Gumbo T
Int J Antimicrob Agents; 2024 May; ():107204. PubMed ID: 38754528
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
[TBL] [Abstract][Full Text] [Related]
20. The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent.
Deshpande D; Srivastava S; Chapagain ML; Lee PS; Cirrincione KN; Pasipanodya JG; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i36-i42. PubMed ID: 28922808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]